Ligand Pharmaceuticals
LGND
305 hedge funds and large institutions have $2.85B invested in Ligand Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 91 increasing their positions, 140 reducing their positions, and 50 closing their positions.
0.81% more ownership
Funds ownership: 203.05% → 203.87% (+0.81%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
8% less funds holding
Funds holding: 330 → 305 (-25)
13% less capital invested
Capital invested by funds: $3.26B → $2.85B (-$413M)
35% less repeat investments, than reductions
Existing positions increased: 91 | Existing positions reduced: 140
36% less call options, than puts
Call options by funds: $53.4M | Put options by funds: $83.9M
42% less first-time investments, than exits
New positions opened: 29 | Existing positions closed: 50
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$38.4M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$18.6M |
| 3 |
TAM
Telemark Asset Management
Boston,
Massachusetts
|
+$17.7M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
+$13.5M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$11.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$28.4M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$26.1M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$18M |
| 4 |
Renaissance Technologies
New York
|
-$15.9M |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$13.6M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PFO
351
Pathstone Family Office
Englewood,
New Jersey
| – | -$2K | -29 | Closed |
|
352
Bessemer Group
Woodbridge,
New Jersey
| – | -$2K | -24 | Closed |
|
|
WEC
353
Winslow Evans & Crocker
Boston,
Massachusetts
| – | -$2K | -16 | Closed |
|
|
AIC
354
Ameritas Investment Company
Lincoln,
Nebraska
| – | -$1K | -11 | Closed |
|
|
IAS
355
IMA Advisory Services
Denver,
Colorado
| – | -$1K | -10 | Closed |
|
LGND Hedge Fund Activity: Q2 2019 in Review
305 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in Ligand Pharmaceuticals (LGND) for Q2 2019, worth a combined $2.85B — down 13% from $3.26B a quarter earlier.
Sellers outnumbered buyers: 50 funds closed out of LGND and 29 opened new positions — a net loss of 21 holders — while 140 trimmed existing stakes and 91 added.
The largest buyer was Invesco, adding an estimated $38.4M. The largest seller was BlackRock, cutting an estimated $28.4M.
- 305 institutional investors held Ligand Pharmaceuticals (LGND) as of Q2 2019, down from 330 in Q1 2019.
- Funds reported $2.85B of Ligand Pharmaceuticals stock for Q2 2019, down 13% quarter-over-quarter.
- 29 funds opened new Ligand Pharmaceuticals positions in Q2 2019 and 50 closed out, a net change of -21 holders.
- The largest Ligand Pharmaceuticals buyer in Q2 2019 was Invesco, an estimated $38.4M added.
- The largest Ligand Pharmaceuticals seller in Q2 2019 was BlackRock, an estimated $28.4M sold.
Based on aggregated 13F filings for Q2 2019.